Arvinas, Inc. Stock News

NEW YORK , May 05, 2025 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against Arvinas, Inc. (“Arvinas” or the “Company”) (NASDAQ:ARVN). The investigation concerns whether Arvinas and/or certain of its officers have violated the federal securities laws.

I favor biotech stocks trading below cash value after setbacks; Arvinas (ARVN) fits this description, dropping 25% on Thursday after ending two Phase 3 trials. ARVN's net cash per share is over $12, presenting a 70% upside from its current $7 stock price. ARVN's remaining pipeline holds minimal value; the investment thesis hinges on its substantial cash reserves and potential for activist share...

BOSTON, MA / ACCESS Newswire / May 2, 2025 / Block & Leviton is investigating Arvinas, Inc. (Nasdaq:ARVN) for potential securities law violations. Investors who have lost money in their Arvinas, Inc. investment should contact the firm to learn more about how they might recover those losses.

Arvinas, Inc. (NASDAQ:ARVN ) Q1 2025 Earnings Conference Call May 1, 2025 8:00 AM ET Company Participants Jeff Boyle - Vice President of Investor Relations John Houston - President and Chief Executive Officer Noah Berkowitz - Chief Medical Officer Andrew Saik - Chief Financial Officer Conference Call Participants Michael Schmidt - Guggenheim Andrew Berens - Leerink Partners Jonathan Miller - Ev...

BOSTON, May 01, 2025 (GLOBE NEWSWIRE) -- Block & Leviton is investigating Arvinas, Inc. (Nasdaq: ARVN) for potential securities law violations. Investors who have lost money in their Arvinas, Inc. investment should contact the firm to learn more about how they might recover those losses.

– Reported positive topline results from the Phase 3 VERITAC-2 trial that support global regulatory filings – – Presented first-in-human data for the Company's first neuroscience program with ARV-102 showing blood-brain barrier penetration and central and peripheral LRRK2 degradation – – Announced the re-prioritization of its vepdegestrant development plan and research portfolio and initiated c...

NEW HAVEN, Conn., April 28, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company working to develop a new class of drugs based on targeted protein degradation, today announced that management will review first quarter 2025 financial results and provide a corporate update during a live webcast on Thursday, May 1, 2025, at 8:00 a.m.

– ARV-393 demonstrated strong synergistic antitumor activity, including complete regressions, in combination with standard-of-care chemotherapy, biologics, and select investigational oral small molecule inhibitors – – Findings support continued evaluation of ARV-393 combinations in non-Hodgkin lymphoma – NEW HAVEN, Conn., April 28, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinic...